Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese Patients

Trial Identifier: D0817R00011
Sponsor: AstraZeneca
NCTID:: NCT04560452
Start Date: March 2021
Primary Completion Date: December 2025
Study Completion Date: December 2025
Condition: Ovarian Cancer; Prostate Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
China Anhui, China
China Beijing, China
China Changsha, China
China Chengdu, China
China Chongqing, China
China Dalian, China
China Dongguan, China
China Foshan, China
China Guangzho, China
China Guangzhou, China
China Guizhou, China
China Hangzhou, China
China Harbin, China
China Henan, China
China Huizhou, China
China JingHou, China
China Langfang, China
China Luzhou, China
China Nanchang, China
China Nanjing, China
China Nantong, China
China Ningbo, China
China Shandong, China
China Shanghai, China
China Shantou, China
China Shenyang, China
China Shenzhen, China
China Shijazhuang, China
China Taiyuan, China
China Tianjin, China
China Xiamen, China
China Xi'an, China
China Yichang, China
China Yunnan, China
China Zhangjiagang, China
China Zhengzhou, China
China, Beijing Beijing, China
China, Shanghai Shanghai, China